Applied Therapeutics Inc. (APLT) shares plummeted by 5.42% in the pre-market session on Monday, December 2, 2024, following a significant downgrade and price target cut by UBS analysts.
According to UBS, they have downgraded their rating on Applied Therapeutics from Buy to Neutral, citing concerns about the company's prospects. Along with the downgrade, UBS has also slashed their price target for the stock from $13 to just $2.
The steep downgrade and price target reduction by a prominent Wall Street firm like UBS appears to be the primary driver behind the sharp sell-off in Applied Therapeutics' shares on Monday morning.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.